

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2015

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	30-0520478
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4520 East-West Highway, 3 rd Floor Bethesda, Maryland	20814
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On May 20, 2015, Sucampo Pharmaceuticals, Inc. (“Company”) will make a corporate update presentation at the 2015 UBS Global Healthcare Conference. The slides from the presentation will also be used at one-on-one meetings with analysts and investors at the conference. All meetings will include written communication comprised of slides. The slides from the presentation are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The corporate update presentation slides dated May 20, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: May 20, 2015

By: /s/ Andrew P. Smith
Name: Andrew P. Smith
Title: Chief Financial Officer

Sucampo Pharmaceuticals, Inc. 2015 UBS Global Healthcare Conference

May 20, 2015

Stan Miele

President, Sucampo Pharma Americas, LLC; SVP, Sales and Marketing



Forward-Looking Statements


This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; the ability of Sucampo to continue to develop the market for AMITIZA; the ability of Sucampo to develop, commercialize or license existing pipeline products or compounds or license or acquire non-prostone products or drug candidates; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally; the effects of competitive products on Sucampo's products; and the exposure to litigation and/or regulatory actions.


No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 10-K as filed with the Securities and Exchange Commission on March 9, 2015 as well as its filings with the Securities and Exchange Commission on Forms 8-K and 10-Q since the filing of the Form 10-K, all of which Sucampo incorporates by reference.

Sucampo Overview

- **Sucampo is a global biopharmaceutical company built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients**
- **Proven track record of successful pharmaceutical product development and approvals**
 - Deep management bench with proven experience in new product development
- **AMITIZA® is flagship product: differentiated profile in an attractive market with a large unmet need**
 - Blue chip partnerships provide global reach and drive outsized revenue growth
- **Robust product pipeline that will build on a strong foundation**
- **Strong financial performance: \$115M revenue for FY 2014 and \$29.5M for Q1 2015, robust balance sheet and cash position**

Clear Strategy to Methodically Build a Leading Bio/Pharma Company






AMITIZA is a Unique and Highly-Differentiated Product

- **Most expansive label in constipation market: 3 indications, 3 patient types**
 - **CIC:** Chronic Idiopathic Constipation
 - **IBS-C:** Irritable Bowel Syndrome with Constipation
 - **OIC:** Opioid Induced Constipation in Adults (non-cancer)
- **Most experienced product: over 9M prescriptions since 2006**
- **Only product with a dual mechanism of action**
 1. Increases intestinal fluid secretion
 2. Stimulates recovery of mucosal barrier function
- **Key product characteristics**
 - Locally-acting
 - Rapid and predictable onset of action
- **Well-tolerated product with established safety profile**
 - No black box warning




Addressing Large Market with Significant Unmet Need


Market MATTY TRx by Category thru Mar 2015



Brand/Generic MATTY TRx thru Mar 2015



Brand TRx by Category thru Mar 2015




OTC Market: additional ~\$800M annually

Accelerating Growth is Evidence of Compelling Value Proposition

U.S. (Takeda)


2014 total prescriptions were 1.3M; all-time yearly high



TRx Scripts
Q1 grew 9% YoY
YTD growth 6%


■ Units

Japan (Abbott)




*Based on Management assumption of 46 capsules per TRx

Multiple Levers Will Drive AMITIZA Outsized Growth



New Market Opportunities

Global prevalence of constipation disorders ranges from 5-18%



Takeda is #1 GI company world wide
Takeda has rights to all markets except Japan (Mylan) and China

*Successful completion of MRP in Austria, Belgium, Germany, Italy, Ireland, Luxembourg, Netherlands, and Spain; Ireland, Belgium, Luxembourg and Netherlands have issued National Marketing Authorization

AMITIZA Life Cycle Management

Expand AMITIZA franchise through new formulation and new indication

1. New Formulation

- Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso-gastric tube fed patients
- Incremental opportunity to address the roughly 40% of adults who have difficulty swallowing pills
- Next step: Phase 3 commence 2H 2015

2. New Pediatric Functional Constipation Indication

- Constipation is one of the most common gastrointestinal complaints in children
- US Prevalence: 18% of pediatric population (13.5M)
- Unmet need: No FDA-approved competition for AMITIZA in pediatric population (black box warning for linaclotide; prucalopride failed in Phase 4)
- Current formulation: older children (6-17 years) who are able to take the current capsule formulation
- Alternate formulation: younger children (6 months and above)



Pipeline

At-A-Glance: Sucampo Pipeline

	CLINICAL FOCUS	STAGE OF CLINICAL DEVELOPMENT			TIMELINE TARGETS		
		LEAD COMPOUNDS	PHASE 1	PHASE 2	PHASE 3	NDA/MAA FILING	APPROVAL
Lifecycle Management	Lubiprostone – Pediatric Functional Constipation (6 years-17 years)			Pivotal: LPI – 2H 2015	Open-Label: LPI – 2H 2015	2016*	2017*
	Lubiprostone – Alternate Formulation (Adults)			FPI – 2H 2015 LPI – 1H 2016		2H 2016*	2017*
	Lubiprostone – Alternate Formulation – Pediatric Functional Constipation (6 months- 6 years)			Pivotal: FPI – 1H 2016 LPI – 1H 2017	Open-Label: FPI – 1H 2016 LPI – 2H 2016	2017*	2018*
Clinical Development	Cobiprostone – Oral Mucositis		FPI – 1H 2015 LPI – 2H 2016		FPI – 2017 LPI – 2018	2018	2019
	Cobiprostone – NERD		FPI – 2H 2014 LPI – 2H 2015		FPI – 2018 LPI – 2018	2020	2021

Received Fast Track Designation for cobiprostone in oral mucositis

■ COMPLETED

■ IN PROGRESS / PROJECTED START

*Pending partner/FDA discussions

Supplementing Existing Pipeline

- ▶ Commenced assessment of external programs
- ▶ Complement existing product pipeline
- ▶ Leverage current skills and experience of Sucampo
- ▶ Therapeutic areas
- ▶ Platform- and technology- agnostic
- ▶ Orphan and specialist products



Financials

Key Facts and Financial Summary

Financial Highlights for Q1 2015

Total Revenue	\$29.5M
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	\$87.5M
Net Income	\$6.4M
EPS	\$0.14
Cash & Equivalents	\$118.8M
Notes Payable	\$25.8M

Financial Highlights for FY 2014

Total Revenue	\$115.5M
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	\$331.6M
Net Income, excluding special items	\$17.9M
EPS, excluding special items	\$0.40

2015 Financial Guidance


Net Income	\$25M - \$30M
EPS	\$0.55 - \$0.65

Upcoming Milestones

Event	Expected Timing
Global partnership agreement for AMITIZA	√
Updated on AMITIZA alternate formulation and PFC development	√
Filed AMITIZA for approval in Canada	√
Initiated MRP to secure approval for AMITIZA (CIC) in additional European markets	√
Decision made on ion channel activator program for LSS	√
Cobiprostone NERD Ph. 2 FPI	√
Cobiprostone oral mucositis Ph. 2 FPI	1H 2015
Approvals for AMITIZA in additional European markets	1H 2015
Lubiprostone alternate formulation Ph. 3 FPI	2H 2015
Lubiprostone PFC (6 years – 17 years) Ph. 3 LPI (pivotal)	2H 2015
Lubiprostone PFC (6 years – 17 years) Ph. 3 LPI (open-label)	2H 2015
Approval of AMITIZA in Canada	2H 2015
Cobiprostone NERD Ph. 2 LPI	2H 2015
AMITIZA IND application approval in China	2H 2015
Lubiprostone alternate formulation Ph. 3 LPI	1H 2016
Lubiprostone PFC (6 months – 6 years) Ph. 3 FPI (pivotal)	1H 2016
Lubiprostone PFC (6 months – 6 years) Ph. 3 FPI (open-label)	1H 2016
File lubiprostone alternate formulation for approval in U.S.	2H 2016
Cobiprostone oral mucositis Ph. 2 LPI	2H 2016
Lubiprostone PFC (6 months – 6 years) LPI (open-label)	2H 2016

Investment Highlights

- Lead product with differentiated profile in an attractive market with a large unmet need
- Blue chip partnerships provide global reach and drive outsized revenue growth
- Multiple levers available to drive sustainable long term growth
- Robust product pipeline that will build on a strong foundation
- Well-defined lifecycle management strategy maximizes franchise value
- Strong financial performance with robust balance sheet and cash position
- Deep management bench with proven experience in new product development



Q&A

